Ranolazine-Induced Reversible T-Wave Inversions with Prolonged QTc Interval; Progressive Multifocal Leukoencephalopathy Linked to Fingolimod; Losartan-Induced Sprue-like Enteropathy; Nivolumab-Induced Psoriasiform Skin Eruption; Hepatitis B Reactivation with Hepatitis C Treatment with Simeprevir and Sofosbuvir.

The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), discuss methods of prevention, and promote reporting of ADRs to the US Food and Drug Administration's (FDA's) MED WATCH program (800-FDA-1088). If you have reported an interesting, preventable ADR to MED WATCH, please consider sharing the account with our readers. Write to Dr. Mancano at ISMP, 200 Lakeside Drive, Suite 200, Horsham, PA 19044 (phone: 215-707-4936; e-mail: mmancano@temple.edu). Your report will be published anonymously unless otherwise requested. This feature is provided by the Institute for Safe Medication Practices (ISMP) in cooperation with the FDA's MED WATCH program and Temple University School of Pharmacy. ISMP is an FDA MED WATCH partner.